




or a pharmaceutically acceptable salt thereof,
wherein:

R_1 is a bond , , ,



wherein X is a halogen and Y is an alkyl group and

wherein  indicates bonding to R_2 at any position
and  indicates bonding to R_2 and the substituent
at any position; and

R_2 is a bond, $-(CY'_2)_n^-$, $-(CY'_2-CY'=CY')_n^-$,


$-(CY'_2-CY'_2-CH=CH)_n^-$, $-(CY'=CY')_n^-$, or $-(CY'_2-\overset{\overset{O}{\parallel}}{C})_n^-$,

wherein Y' is hydrogen or an alkyl group and wherein n
is 1 to 6; and

R_3 is $-Y''$, $-OH$, $-NH_2$, $-N^+(Y'')_3$, $-COOH$, $-COO^-$,
 $-SO_3H$, $-SO_3^-$, $-C-PO_3H_2$ or $-C-PO_3H^-$, wherein Y'' is an
alkyl group.

Fig. 1A


10051367 012202



or a pharmaceutically acceptable salt thereof,

wherein:

each R_1' is independently a bond, ,



wherein Y'' is an alkyl group, and wherein indicates bonding to R_1' at any position and indicates bonding to R_2' and the R_1' phenyl substituent at any position;


each R_2' is independently a bond, or $-(CH_2)_n-$ wherein n is 1-4,

each R_3' is independently $-Y''$, $-Y'''$, $-H$, $-OH$, $-OY''$, $-NO_2$, $-CN$, $-NH_2$, $-COOH$, $-COY''$, $-COO^-$, or a heterocyclic group, wherein Y'' is as defined above and Y''' is a primary, secondary, tertiary or quaternary amine.


Fig. 1B.

2022107965001

Fig. 1C



I




II

R₁ through R₈ are, independently, -H, alkyl, 2-hydroxyalkyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid, alkyl ester of carboxylic acid, carboxylic acid, glucuronyl or glyceryl ester of carboxylic acid, 1,2-dihydroxyalkyl, acetyl, vinyl, glycosyl or, taurate, and


β, γ and δ are, independently, -H, acetyl, glyceryl, benzoate, phenylsulfonate, 2-, or 3-, or 4-N-alkyl-pyridyl, nitrophenyl, halophenyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid.

Fig 1D




20251367-01202

Fig. 1E




or pharmaceutically acceptable salt thereof
wherein:

R_1 and R_2 are the same and are:




R_3 and R_4 are the same and are:



Y is halogen or $-CO_2X$,

each X is the same or different and is an alkyl and each R_5 is the same or different (preferably the same) and is H or alkyl.

Fig 1 E



or pharmaceutically acceptable salt thereof

wherein:

R₁ and R₃ are, independently:

-CO₂C₁₋₄ alkyl; or

-CO₂(CH₂)_nCX₃, wherein X is halogen and n = 1 to 3;

R₂ is:

-H

-C₁₋₄alkyl

-COOH

-CO₂C₁₋₄ alkyl,

-CO₂(CH₂)_nCX₃, wherein X is halogen and n = 1 to 3,

-CON(CH₃)₂, or

-CX₃, wherein X is halogen; and

R₄ is:

-H,

-C₁₋₄alkyl

-COOH,


-CO₂C₁₋₄ alkyl,

-CO₂(CH₂)_nCX₃, wherein X is halogen and n = 1 to 3,

-CON(CH₃)₂, or


-CX₃, wherein X is halogen.

Fig 1G



I

or



II,

or pharmaceutically acceptable salt thereof,

wherein

each R is, independently, a C₁-C₈ alkyl group,

and

each P is, independently, an electron withdrawing group or hydrogen.

Fig. 1H

2022FO/29E5007





Fig. 1H continued

20251367.01202




Figure 2A





Figure 2B



Effect of Radiation & AEDL 10113 on Mammary Adenocarcinoma




Fig 2C

Tumor Growth Inhibition R3230 AC Mammary Adenocarcinoma in Fisher rats





Figure 4

Tumor growth inhibition (s.q. chambers)

Dose = 6 mg/kg



Tumor Angiogenesis

Dose = 6 mg/kg






Figure 6



Catalytic Antioxidant Metalloporphyrin
[MnTBAP]

2022107987001

Figure 7



10054367-012202

202210" 29ET500F

Figure 8





Figure 9

A



B








Figure 10



20220709ET500T

10051367.03202

Figure 11




Figure 12




Figure 13A




Figure 13B




Figure 14




Figure 15




FIGURE 16
2022FO" & SEET 500T

A549 3H-Thymidine uptake at 24 hours




Figure 17








Figure 18

INC-01 Blinded Mucositis Scores



Percentage of Study Days with Ulceration as Indicated by a Score of 3 or Greater

